Cosmo (COPN) Hisse Özeti
Cosmo Pharmaceuticals N.V. dünya çapında gastroenteroloji, dermatoloji ve sağlık teknolojilerine yönelik ürünlerin geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 2/6 |
COPN Community Fair Values
Create NarrativeSee what 154 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CHF 100
FV
33.2% değerinin altında içsel indirim3k
users have viewed this narrative8users have liked this narrative
0users have commented on this narrative
84users have followed this narrative
Cosmo N.V. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | CHF 66.80 |
| 52 Haftanın En Yüksek Seviyesi | CHF 129.40 |
| 52 Haftanın En Düşük Seviyesi | CHF 53.40 |
| Beta | 1.48 |
| 1 Aylık Değişim | -14.47% |
| 3 Aylık Değişim | -12.91% |
| 1 Yıllık Değişim | 18.65% |
| 3 Yıllık Değişim | 47.46% |
| 5 Yıllık Değişim | -24.09% |
| Halka arzdan bu yana değişim | 199.55% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 05
COPN: Alopecia Filings Will Drive CHF 160 Upside Potential
Narrative Update on Cosmo Analysts have raised their price target for Cosmo to CHF 160 from CHF 130, citing updated expectations for revenue growth, profit margins, and future P/E assumptions as key reasons for the change. What's in the News Cosmo reported positive 12 month Phase III results for Clascoterone 5% topical solution in men with mild to moderate androgenetic alopecia, with the program described as the largest Phase III clinical program conducted for a topical treatment in this indication.
Anlatı Güncellemesi • May 16
Cosmo Pharmaceuticals Will Achieve Its Target Price of €95–110 in 12 Months
Below is a full institutional-style comps + valuation (target price) for Cosmo Pharmaceuticals N.V. , integrating: ✅ FY2025 audited report (your PDF) ✅ Product + pipeline positioning (Cosmo site + report) ✅ Sell-side-style benchmarking framework (SWS-type approach: specialty pharma + medtech AI comps) 1) Investment framing (key drivers) Business mix (unique hybrid) Cosmo is a multi-vertical life sciences platform : MedTech AI (GI Genius™) → high-growth SaaS/MedTech multiple Dermatology (Winlevi + Clascoterone) → specialty pharma growth GI pharma + royalties (MMX platform) → stable cash flows CDMO → low multiple, stabilizer Important: market struggles to value hybrid → mispricing opportunity 2) Financial baseline (FY2025) Core metrics Revenue: €104.2m Recurring revenue: €88.1m (+15%) EBITDA: €9.5m Net income: –€3.5m Cash + investments: €128.3m Market cap: €1.98bn 2025 distorted due to: loss of €186m Medtronic milestone (2024) underlying recurring growth intact (+15%) 3) Product + pipeline valuation bridge A. Commercial assets (anchor value) 1.Anlatı Güncellemesi • May 11
COPN: CHF 160 Outlook Will Rely On Successful Alopecia Regulatory Filings
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins and future P/E. These changes collectively support a slightly lower fair value estimate and a modestly higher discount rate in their models.Anlatı Güncellemesi • Apr 23
COPN: Higher CHF 160 Outlook Will Depend On Upcoming Alopecia Filing
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions on fair value, revenue growth, profit margins and future P/E that contribute to a higher overall valuation framework. Analyst Commentary While the higher CHF 160 target reflects updated valuation work, bearish analysts still flag several areas where expectations could prove demanding if underlying assumptions do not play out as planned.Recent updates
Anlatı Güncellemesi • Jun 05
COPN: Alopecia Filings Will Drive CHF 160 Upside Potential
Narrative Update on Cosmo Analysts have raised their price target for Cosmo to CHF 160 from CHF 130, citing updated expectations for revenue growth, profit margins, and future P/E assumptions as key reasons for the change. What's in the News Cosmo reported positive 12 month Phase III results for Clascoterone 5% topical solution in men with mild to moderate androgenetic alopecia, with the program described as the largest Phase III clinical program conducted for a topical treatment in this indication.Anlatı Güncellemesi • May 16
Cosmo Pharmaceuticals Will Achieve Its Target Price of €95–110 in 12 Months
Below is a full institutional-style comps + valuation (target price) for Cosmo Pharmaceuticals N.V. , integrating: ✅ FY2025 audited report (your PDF) ✅ Product + pipeline positioning (Cosmo site + report) ✅ Sell-side-style benchmarking framework (SWS-type approach: specialty pharma + medtech AI comps) 1) Investment framing (key drivers) Business mix (unique hybrid) Cosmo is a multi-vertical life sciences platform : MedTech AI (GI Genius™) → high-growth SaaS/MedTech multiple Dermatology (Winlevi + Clascoterone) → specialty pharma growth GI pharma + royalties (MMX platform) → stable cash flows CDMO → low multiple, stabilizer Important: market struggles to value hybrid → mispricing opportunity 2) Financial baseline (FY2025) Core metrics Revenue: €104.2m Recurring revenue: €88.1m (+15%) EBITDA: €9.5m Net income: –€3.5m Cash + investments: €128.3m Market cap: €1.98bn 2025 distorted due to: loss of €186m Medtronic milestone (2024) underlying recurring growth intact (+15%) 3) Product + pipeline valuation bridge A. Commercial assets (anchor value) 1.Anlatı Güncellemesi • May 11
COPN: CHF 160 Outlook Will Rely On Successful Alopecia Regulatory Filings
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins and future P/E. These changes collectively support a slightly lower fair value estimate and a modestly higher discount rate in their models.Anlatı Güncellemesi • Apr 23
COPN: Higher CHF 160 Outlook Will Depend On Upcoming Alopecia Filing
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions on fair value, revenue growth, profit margins and future P/E that contribute to a higher overall valuation framework. Analyst Commentary While the higher CHF 160 target reflects updated valuation work, bearish analysts still flag several areas where expectations could prove demanding if underlying assumptions do not play out as planned.
Anlatı Güncellemesi • Apr 08
COPN: Recent Share Placement Will Support Improved Margins And Future Earnings Potential
Analysts have adjusted their price target on Cosmo Pharmaceuticals to CHF 140.45 from CHF 147.89, citing updated views on fair value, revenue growth, profit margins and future P/E assumptions. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares on February 3, 2026 (Key Developments).
Anlatı Güncellemesi • Mar 25
COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside
Analysts have lifted their price target on Cosmo Pharmaceuticals from CHF 104.55 to around CHF 123.72, reflecting updated assumptions for higher revenue growth, a different profit margin profile, and a higher future P/E multiple. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares that represent 5.3% of the company's outstanding shares as of February 3, 2026 (Key Developments).Anlatı Güncellemesi • Mar 10
COPN: Recent Share Placement Will Support Stronger Revenue And Margin Outlook
Analysts have nudged their price target on Cosmo Pharmaceuticals slightly lower to around CHF148 from approximately CHF150, reflecting updated assumptions on fair value, revenue growth and profit margins while keeping future P/E expectations broadly in line with prior views. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares, which represent 5.3% of the company's outstanding shares, on February 3, 2026 (Key Developments).Anlatı Güncellemesi • Feb 24
COPN: Recent Share Placement Will Support Bullish Long Term Outlook
Analysts have trimmed their price target on Cosmo Pharmaceuticals by CHF 0.00 to reflect slightly updated assumptions on revenue growth, profit margins and future P/E, while keeping their overall fair value view effectively unchanged. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares, equal to 5.3% of outstanding shares, on February 3, 2026 (Key Developments).Anlatı Güncellemesi • Feb 10
COPN: EU Acne Approval And Share Placement Will Support Bullish Outlook
Analysts now set their price target for Cosmo Pharmaceuticals closer to €150, up from about €102, citing updated assumptions for revenue growth, profit margins and future P/E, which feed into a higher fair value estimate. What's in the News Cosmo Pharmaceuticals completed a private placement of 937,086 treasury shares, representing 5.3% of its outstanding shares, with a single institutional investor on February 3, 2026.Anlatı Güncellemesi • Jan 26
COPN: EU Acne Launch And Margin Assumptions Will Likely Keep Shares Fairly Valued
Analysts have moderately raised their price target on Cosmo Pharmaceuticals, citing updates to their fair value estimate along with revised assumptions for revenue growth, profit margins and future P/E. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream) following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).Anlatı Güncellemesi • Jan 11
COPN: EU Acne Authorization And Rollout Will Likely Leave Shares Overextended
Analysts have trimmed their price target for Cosmo Pharmaceuticals by roughly €0.46, reflecting slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple in their updated models. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream), following a prior positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).Anlatı Güncellemesi • Dec 24
COPN: EU Acne Approval And Rollout Are Expected To Support Balanced Outlook
Analysts have modestly trimmed their price target for Cosmo Pharmaceuticals by approximately $0.48, reflecting refined assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for the treatment of acne vulgaris in adults and adolescents 12 to under 18 years, with adolescent use limited to facial application only Key Developments Cosmo Pharmaceuticals and Glenmark Pharmaceuticals secure EU wide approval enabling commercialization of Winlevi across 15 countries, including France, Spain, the Netherlands, and the Nordics Key Developments Glenmark prepares to launch Winlevi in a staged rollout across Bulgaria, the Czech Republic, Denmark, Finland, Hungary, Iceland, Norway, Poland, Portugal, Romania, Slovakia, Sweden, and other approved EU markets Key Developments Valuation Changes The Fair Value Estimate has fallen slightly to CHF 98.24 from CHF 98.72, reflecting a modest downward adjustment in intrinsic valuation.Anlatı Güncellemesi • Dec 09
COPN: EU Authorization And Launch Partnership Are Expected To Support Balanced Outlook
Analysts have nudged their price target for Cosmo Pharmaceuticals slightly higher to approximately $98.72 per share from about $98.59, citing expectations for stronger revenue growth that more than offset a modestly lower projected profit margin and valuation multiple. What's in the News European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for treatment of acne vulgaris in adults and adolescents aged 12 to under 18 years, with adolescent use restricted to facial application EU Marketing Authorization Approval follows a positive CHMP opinion issued on August 25, 2025, confirming regulatory momentum for Cosmo Pharmaceuticals dermatology portfolio EU Marketing Authorization Commercial launch of Winlevi to be led by partner Glenmark Pharmaceuticals across 15 European countries, including France, Spain, the Netherlands, and the Nordics, expanding Cosmo Pharmaceuticals geographic reach EU Marketing Authorization Valuation Changes Fair Value Estimate has risen slightly to CHF 98.72 from CHF 98.59 per share, reflecting a marginal upward revision to intrinsic value.Analiz Makalesi • Dec 05
Cosmo Pharmaceuticals N.V. (VTX:COPN) Stocks Shoot Up 35% But Its P/E Still Looks Reasonable
The Cosmo Pharmaceuticals N.V. ( VTX:COPN ) share price has done very well over the last month, posting an excellent...Anlatı Güncellemesi • Nov 25
COPN: EU Approval And Expanded Distribution Expected To Drive Share Performance
Analysts have raised their price target for Cosmo Pharmaceuticals from $87.81 to $98.59. They cite updated fair value assessments and recent model adjustments as the reasons for the change.Anlatı Güncellemesi • Sep 04
Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges
Cosmo Pharmaceuticals’ consensus revenue growth forecasts have strengthened and its future P/E valuation has decreased, but despite these more favourable fundamentals, the consensus analyst price target was only marginally reduced from CHF88.37 to CHF87.81. What's in the News Issued FY2025 guidance: total revenues expected between EUR 102 million and EUR 107 million, with recurring revenues of EUR 85 million to EUR 90 million and project-based revenues of EUR 17 million.
Yeni Anlatı • Mar 17
Clascoterone Trials Completion And AI Expansion Will Open Future Markets
Strong cash position and no debt provide flexibility for strategic investments, boosting future profitability and earnings.Analiz Makalesi • Jan 23
Weekly Picks: NLBR’s vision, MNSO’s expansion plans and COPN’s opportunity
This weeks picks cover the promising product pipeline from a Cosmo Pharmaceutical, how NLBR bank could almost double its revenue and earnings, and why MINISO Group’s aggressive store expansion plans will pay off.Yeni Anlatı • Jan 20
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Revenue: €265.7 million, representing a 186% year-over-year increase from €92.8 million in 2023. This includes €185 million in non-recurring revenues from Medtronic linked to the December 2023 expandeAnaliz Makalesi • Nov 22
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
When you see that almost half of the companies in the Pharmaceuticals industry in Switzerland have price-to-sales...Analiz Makalesi • May 02
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
With a price-to-sales (or "P/S") ratio of 12.2x Cosmo Pharmaceuticals N.V. ( VTX:COPN ) may be sending very bearish...Analiz Makalesi • Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Cosmo Pharmaceuticals N.V.'s ( VTX:COPN ) recent earnings didn't contain any...Analiz Makalesi • Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Celebrations may be in order for Cosmo Pharmaceuticals N.V. ( VTX:COPN ) shareholders, with the analysts delivering a...Analiz Makalesi • Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Cosmo Pharmaceuticals N.V.'s ( VTX:COPN ) price-to-earnings (or "P/E") ratio of 67x might make it look like a strong...Analiz Makalesi • Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week, you might have seen that Cosmo Pharmaceuticals N.V. ( VTX:COPN ) released its interim result to the market...Analiz Makalesi • Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) announced strong profits, but the stock was stagnant. We did some digging, and...Hissedar Getirileri
| COPN | CH Pharmaceuticals | CH Pazar | |
|---|---|---|---|
| 7D | -5.9% | -0.9% | 0.9% |
| 1Y | 18.7% | 27.5% | 15.2% |
Getiri vs. Endüstri: COPN geçen yıl % 27.5 oranında getiri sağlayan Swiss Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: COPN geçen yıl % 15.2 oranında getiri sağlayan Swiss Piyasasını aştı.
Fiyat Oynaklığı
| COPN volatility | |
|---|---|
| COPN Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.2% |
İstikrarlı Hisse Senedi Fiyatı: COPN hisse senedi fiyatı, son 3 ayda Swiss piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: COPN 'nin haftalık oynaklığı ( 6% ) geçen yıl boyunca sabit kaldı, ancak hala Swiss hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1997 | 325 | Giovanni Di Napoli | www.cosmohealthconfidence.com |
Cosmo Pharmaceuticals N.V. dünya çapında gastroenteroloji, dermatoloji ve sağlık teknolojilerine yönelik ürünlerin geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirket, kolorektal lezyonları tespit etmek için gerçek zamanlı olarak yapay zeka kullanan bilgisayar destekli bir sistem olan GI Genius; akne vulgaris tedavisinde ciltte kullanılan reçeteli bir ilaç olan Winlevi; aktif, hafif ila orta dereceli ülseratif kolitin remisyona girmesine yardımcı olmak için onaylanmış günde bir kez mesalamin tablet olan Lialda/Mezavant/Mesavancol; budesonidi doğrudan kolon lümenine ileten oral bir tablet formülasyonu olan Uceris/Cortiment'i sunmaktadır; Eleview, endoskopistlerin gastrointestinal lezyonları daha hızlı ve daha az riskli bir şekilde eksize etmesini sağlayan enjekte edilebilir bir bileşim; Lumeblue, kolonoskopiler sırasında kolorektal lezyonların görüntülenmesi için bir tanı ilacı; Aemcolo/Relafalk, seyahat edenlerin ishalinin tedavisi için onaylanmış tablet şeklinde bir farmasötik ilaç ürünü; ve Byfavo, intravenöz benzodiazepin sedatif/anestezik. Ayrıca, Faz III çalışmalarında olan ve kafa derisindeki androjen reseptörlerini hedef alan yeni bir androjen reseptör inhibitörü olan Breezula'yı; distal ülseratif kolit ve proktit tedavisi için Faz II klinik çalışmalarında olan Rifamycin %1 lavmanı geliştirmektedir; Safra asidi diyaresinin tedavisi için klinik öncesi çalışmalarda olan Colesevelam; ve katı tümörlerin tedavisi için Faz I klinik çalışmasında olan oral Androjen reseptörü ve glukokortikoid reseptör antagonisti Cortexolone 17a-valerate-21-propionate'in yanı sıra Cosmo'nun AI teknolojisi olan GI Genius akıllı endoskopi sistemini sağlar.
Cosmo N.V. Temel Bilgiler Özeti
| COPN temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | CHF 1.11b |
| Kazançlar(TTM) | -CHF 3.34m |
| Gelir(TTM) | CHF 96.44m |
11.2x
P/S Oranı-323.8x
F/K OranıCOPN aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| COPN gelir tablosu (TTM) | |
|---|---|
| Gelir | €104.17m |
| Gelir Maliyeti | €53.62m |
| Brüt Kâr | €50.56m |
| Diğer Giderler | €54.16m |
| Kazançlar | -€3.61m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
Jul 23, 2026
| Hisse başına kazanç (EPS) | -0.22 |
| Brüt Marj | 48.53% |
| Net Kâr Marjı | -3.46% |
| Borç/Özkaynak Oranı | 0.06% |
COPN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
2.9%
Mevcut Temettü Verimi-929%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/22 08:31 |
| Gün Sonu Hisse Fiyatı | 2026/06/22 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Cosmo N.V. 11 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Estelle Bétrisey | Berenberg |
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |